Taken together, our data suggest that although intestinal barrier function was disturbed in FrFC-fed mice, enriching the diet with phosphatidylcholine had no effect on these alterations but rather protected the liver from the development of MASLD through suppressing the LPS-dependent activation of PPARγ2 and, subsequently, NFκB in liver tissue. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.